Article information
Abstract
Hemodialysis patient with chronic HCV infection, who was started on monotherapy with interferon. Qualitative HCV RNA remained positive at 12 weeks of treatment; ribavirin was associated. HCV RNA was negative at week 24 and treatment was extended to 72 weeks. HCV RNA negative six months after treatment.
Keywords:
hepatitis C virus
hemodialysis
treatment
interferon
ribavirin
Full text is only available in PDF
References
[1.]
C.E. Gordon, K. Uhlig, J. Lau, C.H. Schmid, A.S. Levey, J.B. Wong.
Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms.
Am J Kidney Dis., 51 (2008), pp. 263-277
[2.]
P. Dattolo, M. Lombardi, G. Ferro, S. Michelassi, T. Cerrai, F. Pizzarelli.
Natural history of HCV infection and risk of death in a cohort of patients on long-term hemodialysis.
G Ital Nefrol., 23 (2006), pp. 585-590
[3.]
F. Fabrizi, P. Martin, V. Dixit, S. Bunnapradist, G. Dulai.
Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies.
Am J Transplant., 5 (2005), pp. 1452-1461
[4.]
D. Carriero, F. Fabrizi, A.J. Uriel, J. Park, P. Martin, D.T. Dieterich.
Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
Int J Artif Organs., 31 (2008), pp. 295-302
[5.]
E. Nakayama, T. Akiba, F. Marumo, C. Sato.
Prognosis of antihepatitis C virus antibody-positive patients on regular hemodialysis therapy.
J Am Soc Nephrol., 11 (2000), pp. 1896-1902
[6.]
E. Gane, H. Pilmore.
Management of chronic viral hepatitis before and after renal transplantation.
Transplantation, 74 (2002), pp. 427-437
[7.]
P. Mathurin, C. Mouquet, T. Poynard, C. Sylla, H. Benalia, C. Fretz, et al.
Impact of hepatitis B and C virus on kidney transplantation outcome.
Hepatology, 29 (1999), pp. 257-263
[8.]
G.A. Knoll, M.R. Tankersley, J.Y. Lee, B.A. Julian, J.J. Curtis.
The impact of renal transplantation on survival in hepatitis C-positive endstage renal disease patients.
Am J Kidney Dis., 29 (1997), pp. 608-614
[9.]
N. Kamar, O. Toupance, M. Buchler, K. Sandres-Saune, J. Izopet, D. Durand, et al.
Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation.
J Am Soc Nephrol., 14 (2003), pp. 2092-2098
[10.]
F. Fabrizi, G. Dulai, V. Dixit, S. Bunnapradist, P. Martin.
Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients.
Aliment Pharmacol Ther., 18 (2003), pp. 1071-1081
[11.]
M.W. Russo, C.D. Goldsweig, I.M. Jacobson, R.S. Brown Jr.
Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.
Am J Gastroenterol., 98 (2003), pp. 1610-1615
[13.]
M. Rendina, A. Schena, N.M. Castellaneta, F. Losito, A.C. Amoruso, G. Stallone, et al.
The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant.
J Hepatol., 46 (2007), pp. 768-774
[14.]
A. Bruchfeld, L. Ståhle, J. Andersson, R. Schvarcz.
Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study.
J Viral Hepat., 8 (2001), pp. 287-292
[15.]
F. Fabrizi, F.F. Poordad, P. Martin.
Hepatitis C infection and the patient with end-stage renal disease.
Hepatology, 36 (2002), pp. 3-10
[16.]
S. Pol, F. Carnot, B. Nalpas, J.L. Lagneau, H. Fontaine, J. Serpaggi, L. Serfaty, P. Bedossa, C. Bréchot.
Reversibility of hepatitis C virus-related cirrhosis.
Hum Pathol., 35 (2004), pp. 107-112
[17.]
S. Maylin, M. Martinot-Peignoux, R. Moucari, N. Boyer, M.P. Ripault, D. Cazals-Hatem, et al.
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.
Gastroenterology, 135 (2008), pp. 821-829
[18.]
U. Mihm, E. Herrmann, C. Sarrazin, S. Zeuzem.
Review article: predicting response in hepatitis C virus therapy.
Aliment Pharmacol Ther., 23 (2006), pp. 1043-1054
[19.]
T. Berg, M. von Wagner, S. Nasser, C. Sarrazin, T. Heintges, T. Gerlach, et al.
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Gastroenterology, 130 (2006), pp. 1086-1097
Copyright © 2010. Elsevier Editora Ltda.. All rights reserved
